Wu M
Department of Biology, University of Leeds, U.K.
Int J Immunopharmacol. 1997 Feb;19(2):83-93. doi: 10.1016/s0192-0561(97)00012-x.
Immunoconjugates or immunotoxins (ITs) are targeting molecules which consist of a monoclonal antibody together with a toxin--thereby they can selectively kill target cells in a highly efficient manner. The use of ITs as a drug targeting approach is one of the most attractive research fields for tumor therapy; however, the study of ITs for the treatment of autoimmune diseases has been given little attention until recently. It has been shown that ITs could help alleviate the symptoms of myasthenia gravis and rheumatoid arthritis in animal models. In the last 3 yr ITs have been used in clinical trials (phase I and phase II) for the treatment of various autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus and psoriasis. This article reviews the main progress on the application of ITs for the therapies of autoimmune diseases. The preliminary results suggest the future may hold some promise, but side effects, in addition to there being no convincing efficacy, remain unresolved.
免疫缀合物或免疫毒素（ITs）是由单克隆抗体与毒素组成的靶向分子，因此它们能够以高效方式选择性地杀死靶细胞。将ITs用作药物靶向方法是肿瘤治疗中最具吸引力的研究领域之一；然而，直到最近，ITs用于治疗自身免疫性疾病的研究才受到较少关注。研究表明，ITs在动物模型中有助于缓解重症肌无力和类风湿性关节炎的症状。在过去3年中，ITs已用于治疗包括类风湿性关节炎、系统性红斑狼疮、胰岛素依赖型糖尿病和牛皮癣在内的各种自身免疫性疾病的临床试验（I期和II期）。本文综述了ITs在自身免疫性疾病治疗应用方面取得的主要进展。初步结果表明未来可能有一定前景，但除了缺乏令人信服的疗效外，副作用问题仍未得到解决。
